| 1 | Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry | 1.9 | 8 | Citations (PDF) |
| 2 | A case of Buerger’s disease with vasculopathy and skin fibrosis requiring differential diagnosis from systemic sclerosis | 0.9 | 0 | Citations (PDF) |
| 3 | Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study | 1.9 | 12 | Citations (PDF) |
| 4 | Epstein–Barr virus-encoded RNA-positive lymphocytes in bone marrow and lymph nodes in an autopsy case of TAFRO syndrome | 0.9 | 0 | Citations (PDF) |
| 5 | A case of immunoglobulin G4–related disease complicated by atopic dermatitis responsive to upadacitinib treatment | 0.9 | 7 | Citations (PDF) |
| 6 | Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness | 6.9 | 18 | Citations (PDF) |
| 7 | Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry | 1.9 | 2 | Citations (PDF) |
| 8 | Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4 | 1.9 | 1 | Citations (PDF) |
| 9 | The abundance of regulatory T cell subsets is associated with the clinical outcomes of sarcoidosis | 1.9 | 1 | Citations (PDF) |
| 10 | Inebilizumab for Treatment of IgG4-Related Disease | 34.5 | 137 | Citations (PDF) |
| 11 | The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib | 2.0 | 1 | Citations (PDF) |
| 12 | Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity: a multi-national, longitudinal cohort study | 1.9 | 7 | Citations (PDF) |
| 13 | An autopsy of a patient with polyarteritis nodosa who developed fatal intestinal perforation accompanied by systemic multiple aneurysms and arterial thrombosis | 0.9 | 0 | Citations (PDF) |
| 14 | Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials | 1.9 | 2 | Citations (PDF) |
| 15 | A case of Erdheim–Chester disease—a mimicker of IgG4-related disease and large vessel vasculitis | 0.9 | 1 | Citations (PDF) |
| 16 | The 2024
APLAR
Consensus on the Management of Lupus Nephritis | 1.6 | 16 | Citations (PDF) |
| 17 | Precision medicine using molecular-target drugs in psoriatic arthritis | 3.5 | 1 | Citations (PDF) |
| 18 | Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib | 3.4 | 31 | Citations (PDF) |
| 19 | Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: <i>Post hoc</i> analysis of the Japanese subpopulation of the TULIP-2 study | 1.9 | 2 | Citations (PDF) |
| 20 | Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial | 1.9 | 4 | Citations (PDF) |
| 21 | Characteristics of patients with polymyalgia rheumatica based on glucocorticoid dose in Japan: A cohort study using routinely collected health data | 1.9 | 3 | Citations (PDF) |
| 22 | A case of newly onset rheumatoid arthritis successfully treated with methotrexate under the antiretrovirus therapy against HIV infection | 0.9 | 0 | Citations (PDF) |
| 23 | Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis | 2.0 | 2 | Citations (PDF) |
| 24 | A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis | 1.9 | 7 | Citations (PDF) |
| 25 | Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus | 3.9 | 9 | Citations (PDF) |
| 26 | Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry | 2.0 | 8 | Citations (PDF) |
| 27 | Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis? | 3.8 | 2 | Citations (PDF) |
| 28 | Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes | 3.9 | 7 | Citations (PDF) |
| 29 | Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study | 1.9 | 5 | Citations (PDF) |
| 30 | Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort | 2.2 | 2 | Citations (PDF) |
| 31 | Accelerated Type VII collagen turnover in systemic sclerosis patients, reflected by serological neo-epitope fragment biomarkers | 3.9 | 2 | Citations (PDF) |
| 32 | Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial | 1.9 | 3 | Citations (PDF) |
| 33 | Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis | 2.0 | 5 | Citations (PDF) |
| 34 | Critical roles of IL-6 signaling in myoblast differentiation of human adipose-derived mesenchymal stem cells | 6.0 | 4 | Citations (PDF) |
| 35 | Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry | 2.0 | 9 | Citations (PDF) |
| 36 | Pursuing Precision Medicine in Managing Rheumatoid Arthritis | 1.6 | 8 | Citations (PDF) |
| 37 | Targeted Therapies for Rheumatoid Arthritis in Super‐Elderly Society: Insights From
FIRST
Registry, Japan | 1.6 | 8 | Citations (PDF) |
| 38 | Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis | 2.0 | 3 | Citations (PDF) |
| 39 | LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT AND REDUCED GLUCOCORTICOID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB | 2.3 | 1 | Citations (PDF) |
| 40 | EFFICACY AND SAFETY OF ELSUBRUTINIB AND UPADACITINIB COMBINATION AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS THROUGH 104 WEEKS | 2.3 | 0 | Citations (PDF) |
| 41 | Efficacy and Safety of Rituximab in Connective Tissue Disease‐Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy | 1.6 | 1 | Citations (PDF) |
| 42 | The Lupus Check 5 Tool: A Practical Approach to Initiating Treatment Reviews in Systemic Lupus Erythematosus | 2.0 | 0 | Citations (PDF) |
| 43 | Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease | 1.7 | 0 | Citations (PDF) |
| 44 | Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study | 3.9 | 2 | Citations (PDF) |
| 45 | SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring | 1.9 | 17 | Citations (PDF) |
| 46 | Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance | 1.9 | 4 | Citations (PDF) |
| 47 | Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4) | 1.9 | 2 | Citations (PDF) |
| 48 | Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease | 1.9 | 8 | Citations (PDF) |
| 49 | Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial | 1.9 | 8 | Citations (PDF) |
| 50 | Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database | 6.9 | 16 | Citations (PDF) |
| 51 | Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI) | 1.9 | 5 | Citations (PDF) |
| 52 | Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases | 1.9 | 95 | Citations (PDF) |
| 53 | The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis | 1.9 | 11 | Citations (PDF) |
| 54 | A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration | 2.5 | 13 | Citations (PDF) |
| 55 | Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis | 1.9 | 7 | Citations (PDF) |
| 56 | Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping | 6.9 | 18 | Citations (PDF) |
| 57 | Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis | 1.9 | 6 | Citations (PDF) |
| 58 | A delayed diagnosis of fascioliasis: The importance of appropriate fecal diagnostic method | 1.3 | 2 | Citations (PDF) |
| 59 | Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4) | 1.9 | 3 | Citations (PDF) |
| 60 | Bimekizumab for the treatment of psoriatic arthritis | 3.5 | 12 | Citations (PDF) |
| 61 | Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study | 1.9 | 8 | Citations (PDF) |
| 62 | Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: A 2-year post-marketing surveillance study | 1.9 | 2 | Citations (PDF) |
| 63 | Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2) | 1.9 | 3 | Citations (PDF) |
| 64 | Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | 2.2 | 12 | Citations (PDF) |
| 65 | Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data | 2.2 | 19 | Citations (PDF) |
| 66 | Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study | 1.6 | 2 | Citations (PDF) |
| 67 | Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis | 3.5 | 9 | Citations (PDF) |
| 68 | GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region | 13.7 | 18 | Citations (PDF) |
| 69 | Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study | 6.9 | 29 | Citations (PDF) |
| 70 | Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial | 10.3 | 28 | Citations (PDF) |
| 71 | Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL | 3.9 | 36 | Citations (PDF) |
| 72 | Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus | 2.3 | 8 | Citations (PDF) |
| 73 | TYK2: an emerging therapeutic target in rheumatic disease | 25.5 | 59 | Citations (PDF) |
| 74 | Occupational Medicine, Go Above and Beyond | 1.7 | 2 | Citations (PDF) |
| 75 | Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease | 2.5 | 4 | Citations (PDF) |
| 76 | Inflammatory Cytokines and Chemokines Are Synergistically Induced in a ROS-Dependent Manner by a Co-Culture of Corneal Epithelial Cells and Neutrophil-like Cells in the Presence of Particulate Matter | 5.7 | 6 | Citations (PDF) |
| 77 | A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry | 2.0 | 11 | Citations (PDF) |
| 78 | P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial. | 1.9 | 1 | Citations (PDF) |
| 79 | Vitamin D efficacy in type 1 and type 2 diabetes | 1.9 | 14 | Citations (PDF) |
| 80 | Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials | 2.0 | 14 | Citations (PDF) |
| 81 | Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years | 6.9 | 16 | Citations (PDF) |
| 82 | Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes | 3.4 | 2 | Citations (PDF) |
| 83 | Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study | 3.9 | 23 | Citations (PDF) |
| 84 | Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study | 1.9 | 4 | Citations (PDF) |
| 85 | CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry | 3.9 | 8 | Citations (PDF) |
| 86 | Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus | 3.9 | 16 | Citations (PDF) |
| 87 | Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib | 1.9 | 1 | Citations (PDF) |
| 88 | A multi-biomarker panel for predicting Tocilizumab response in Rheumatoid arthritis patients | 4.0 | 8 | Citations (PDF) |
| 89 | Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease | 6.0 | 14 | Citations (PDF) |
| 90 | Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study | 2.0 | 4 | Citations (PDF) |
| 91 | Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&lt;65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials | 1.9 | 4 | Citations (PDF) |
| 92 | Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies | 2.2 | 2 | Citations (PDF) |
| 93 | The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study | 1.9 | 2 | Citations (PDF) |
| 94 | Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study | 2.0 | 2 | Citations (PDF) |
| 95 | Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry | 3.9 | 7 | Citations (PDF) |
| 96 | Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review | 1.9 | 1 | Citations (PDF) |
| 97 | Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis | 3.9 | 9 | Citations (PDF) |
| 98 | Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies | 2.0 | 17 | Citations (PDF) |
| 99 | Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis | 1.9 | 15 | Citations (PDF) |
| 100 | Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus | 3.9 | 23 | Citations (PDF) |
| 101 | Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus | 2.3 | 2 | Citations (PDF) |
| 102 | Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study | 3.9 | 6 | Citations (PDF) |
| 103 | Residual symptoms: Unmet needs for rheumatoid arthritis patients who achieved low clinical disease activity 2024, 4, 19-27 | | 1 | Citations (PDF) |
| 104 | Fine-tuning SLE treatment: the potential of selective TYK2 inhibition | 3.9 | 8 | Citations (PDF) |
| 105 | The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis | 1.9 | 12 | Citations (PDF) |
| 106 | Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren’s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials | 1.9 | 12 | Citations (PDF) |
| 107 | Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan | 1.9 | 31 | Citations (PDF) |
| 108 | Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset | 1.9 | 13 | Citations (PDF) |
| 109 | Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4) | 1.9 | 6 | Citations (PDF) |
| 110 | Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years | 1.9 | 6 | Citations (PDF) |
| 111 | Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study | 1.9 | 11 | Citations (PDF) |
| 112 | Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab | 0.9 | 8 | Citations (PDF) |
| 113 | Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE | 1.9 | 13 | Citations (PDF) |
| 114 | Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model | 1.9 | 21 | Citations (PDF) |
| 115 | Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3) | 1.9 | 10 | Citations (PDF) |
| 116 | Development of targeted therapies in IgG4-related disease | 1.9 | 7 | Citations (PDF) |
| 117 | Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE | 1.9 | 13 | Citations (PDF) |
| 118 | Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population | 1.9 | 19 | Citations (PDF) |
| 119 | Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study | 6.1 | 5 | Citations (PDF) |
| 120 | Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial) | 1.9 | 34 | Citations (PDF) |
| 121 | Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial) | 1.9 | 32 | Citations (PDF) |
| 122 | Lower injection‐site reactions and long‐term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post‐hoc analysis of a double‐blind, randomized, phase III comparative study and its open‐label extension in patients with rheumatoid arthritis | 1.6 | 6 | Citations (PDF) |
| 123 | A case of giant cell arteritis complicated by polymyalgia rheumatica with scalp necrosis and refractory jaw claudication | 0.9 | 0 | Citations (PDF) |
| 124 | A case of glucocorticoid-resistant adult Still’s disease complicated by pulmonary hypertension and interstitial lung disease | 0.9 | 2 | Citations (PDF) |
| 125 | TGF-β3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus | 1.9 | 17 | Citations (PDF) |
| 126 | A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus | 6.1 | 148 | Citations (PDF) |
| 127 | Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease | 1.9 | 51 | Citations (PDF) |
| 128 | Perspectives on current and emerging therapies for immunoglobulin G4–related disease | 1.9 | 33 | Citations (PDF) |
| 129 | Illustrations of rheumatoid arthritis symptoms to promote communication between patients and physicians | 1.9 | 8 | Citations (PDF) |
| 130 | Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis | 1.9 | 29 | Citations (PDF) |
| 131 | Possible involvement of CXCR3-CXCR6 + CD4 + T cells in Langerhans cell histiocytosis | 1.9 | 1 | Citations (PDF) |
| 132 | Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis | 1.9 | 4 | Citations (PDF) |
| 133 | A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia | 6.0 | 26 | Citations (PDF) |
| 134 | Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies | 2.0 | 4 | Citations (PDF) |
| 135 | JAK inhibitors for rheumatoid arthritis | 3.9 | 86 | Citations (PDF) |
| 136 | Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials | 3.9 | 33 | Citations (PDF) |
| 137 | Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis | 3.9 | 206 | Citations (PDF) |
| 138 | Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug | 1.9 | 26 | Citations (PDF) |
| 139 | Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data | 2.0 | 2 | Citations (PDF) |
| 140 | Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus | 1.9 | 7 | Citations (PDF) |
| 141 | Treatment of lupus nephritis: consensus, evidence and perspectives | 25.5 | 124 | Citations (PDF) |
| 142 | Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis | 2.0 | 14 | Citations (PDF) |
| 143 | Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020 | 1.9 | 11 | Citations (PDF) |
| 144 | A Cross-Trait Genetic Correlation Study Identified Eight Diseases and Traits Associated with Psoriasis | 2.3 | 2 | Citations (PDF) |
| 145 | The management of women of childbearing age with rheumatoid arthritis: an expert report | 3.5 | 3 | Citations (PDF) |
| 146 | The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study | 3.9 | 4 | Citations (PDF) |
| 147 | Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials | 1.6 | 14 | Citations (PDF) |
| 148 | Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study | 0.9 | 1 | Citations (PDF) |
| 149 | Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus | 4.2 | 9 | Citations (PDF) |
| 150 | B cell activation via immunometabolism in systemic lupus erythematosus | 4.9 | 42 | Citations (PDF) |
| 151 | Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial | 6.9 | 9 | Citations (PDF) |
| 152 | High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production | 6.3 | 47 | Citations (PDF) |
| 153 | A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience | 2.5 | 41 | Citations (PDF) |
| 154 | Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce | 25.5 | 26 | Citations (PDF) |
| 155 | Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis | 3.0 | 60 | Citations (PDF) |
| 156 | Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial | 0.8 | 26 | Citations (PDF) |
| 157 | Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate | 2.0 | 4 | Citations (PDF) |
| 158 | Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database | 1.6 | 6 | Citations (PDF) |
| 159 | Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome | 2.1 | 4 | Citations (PDF) |
| 160 | Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study | 6.9 | 40 | Citations (PDF) |
| 161 | Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis | 3.9 | 7 | Citations (PDF) |
| 162 | Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook | 3.5 | 9 | Citations (PDF) |
| 163 | Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses | 2.0 | 4 | Citations (PDF) |
| 164 | Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis | 2.0 | 9 | Citations (PDF) |
| 165 | Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives | 2.3 | 5 | Citations (PDF) |
| 166 | Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry | 2.0 | 7 | Citations (PDF) |
| 167 | Neutrophil extracellular trap induction through peptidylarginine deiminase 4 activity is involved in 2,4,6-trinitrobenzenesulfonic acid-induced colitis | 2.6 | 5 | Citations (PDF) |
| 168 | Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region | 2.8 | 45 | Citations (PDF) |
| 169 | Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study | 1.9 | 14 | Citations (PDF) |
| 170 | Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2) | 1.9 | 11 | Citations (PDF) |
| 171 | Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials | 1.9 | 47 | Citations (PDF) |
| 172 | Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort | 1.9 | 18 | Citations (PDF) |
| 173 | Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry | 1.9 | 31 | Citations (PDF) |
| 174 | Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND | 2.3 | 7 | Citations (PDF) |
| 175 | A Japanese patient with anti-PM/Scl and centromere antibody-positive scleroderma-amyopathic dermatomyositis overlap syndrome who developed renal crisis | 0.9 | 1 | Citations (PDF) |
| 176 | Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis | 1.9 | 9 | Citations (PDF) |
| 177 | Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study | 4.5 | 5 | Citations (PDF) |
| 178 | Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis | 1.9 | 7 | Citations (PDF) |
| 179 | A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years | 1.9 | 7 | Citations (PDF) |
| 180 | Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials | 1.9 | 4 | Citations (PDF) |
| 181 | Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans) | 1.9 | 4 | Citations (PDF) |
| 182 | Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus | 2.9 | 11 | Citations (PDF) |
| 183 | An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus | 1.9 | 47 | Citations (PDF) |
| 184 | Clinical features of Behçet’s disease patients with joint symptoms in Japan: A national multicenter study | 1.9 | 6 | Citations (PDF) |
| 185 | mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors | 1.9 | 7 | Citations (PDF) |
| 186 | Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose:post hocanalysis of a randomized, placebo-controlled, phase 4 study | 1.9 | 6 | Citations (PDF) |
| 187 | Apremilast in a Japanese subgroup with Behçet’s syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study | 1.9 | 15 | Citations (PDF) |
| 188 | Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study | 1.9 | 2 | Citations (PDF) |
| 189 | Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1) | 1.9 | 16 | Citations (PDF) |
| 190 | Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance | 1.9 | 8 | Citations (PDF) |
| 191 | Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3) | 1.9 | 7 | Citations (PDF) |
| 192 | Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study | 3.4 | 10 | Citations (PDF) |
| 193 | Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | 25.5 | 478 | Citations (PDF) |
| 194 | Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study | 4.6 | 11 | Citations (PDF) |
| 195 | A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease | 0.9 | 11 | Citations (PDF) |
| 196 | Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study | 1.9 | 5 | Citations (PDF) |
| 197 | Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study | 3.9 | 99 | Citations (PDF) |
| 198 | Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus | 3.5 | 10 | Citations (PDF) |
| 199 | Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review | 3.1 | 19 | Citations (PDF) |
| 200 | Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry | 3.1 | 18 | Citations (PDF) |
| 201 | Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial | 1.9 | 4 | Citations (PDF) |
| 202 | Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus | 2.4 | 28 | Citations (PDF) |
| 203 | Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance | 3.4 | 16 | Citations (PDF) |
| 204 | Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease | 3.9 | 16 | Citations (PDF) |
| 205 | A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators | 0.9 | 2 | Citations (PDF) |
| 206 | Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry | 3.9 | 71 | Citations (PDF) |
| 207 | Dawn of Precision Medicine in Psoriatic Arthritis | 2.4 | 8 | Citations (PDF) |
| 208 | ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study | 3.9 | 41 | Citations (PDF) |
| 209 | Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials | 6.9 | 125 | Citations (PDF) |
| 210 | Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD | 1.9 | 17 | Citations (PDF) |
| 211 | Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan | 2.4 | 9 | Citations (PDF) |
| 212 | Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet’s disease: Case report and the review of literature | 0.9 | 6 | Citations (PDF) |
| 213 | Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus | 5.8 | 7 | Citations (PDF) |
| 214 | A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab | 0.9 | 10 | Citations (PDF) |
| 215 | Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus | 1.9 | 24 | Citations (PDF) |
| 216 | Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis | 1.9 | 4 | Citations (PDF) |
| 217 | Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study | 3.9 | 13 | Citations (PDF) |
| 218 | P192 Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials | 1.9 | 0 | Citations (PDF) |
| 219 | OA29 Clinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to methotrexate initially treated with filgotinib or adalimumab during the Phase 3 Parent Trial | 1.9 | 1 | Citations (PDF) |
| 220 | P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis | 1.9 | 2 | Citations (PDF) |
| 221 | Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials | 6.9 | 42 | Citations (PDF) |
| 222 | Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus | 6.9 | 50 | Citations (PDF) |
| 223 | Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis | 6.1 | 57 | Citations (PDF) |
| 224 | Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis 2022, 1, 32 | | 2 | Citations (PDF) |
| 225 | Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component | 6.9 | 70 | Citations (PDF) |
| 226 | Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study | 3.9 | 35 | Citations (PDF) |
| 227 | Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contribution Rate | 4.6 | 4 | Citations (PDF) |
| 228 | Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus | 6.9 | 71 | Citations (PDF) |
| 229 | Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes | 2.4 | 7 | Citations (PDF) |
| 230 | Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results | 1.9 | 8 | Citations (PDF) |
| 231 | Management of non‐renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements | 1.6 | 12 | Citations (PDF) |
| 232 | Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials | 2.0 | 1 | Citations (PDF) |
| 233 | Management of chronic rheumatic diseases in women 18–45 years of age in Asia Pacific: insights from patient and clinician surveys | 2.4 | 5 | Citations (PDF) |
| 234 | Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression | 3.9 | 11 | Citations (PDF) |
| 235 | Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells | 6.0 | 5 | Citations (PDF) |
| 236 | Remission of Granulomatosis with Polyangiitis Only After Resection of a Pulmonary Nodule | 0.8 | 1 | Citations (PDF) |
| 237 | Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease | 3.4 | 26 | Citations (PDF) |
| 238 | Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study | 2.0 | 2 | Citations (PDF) |
| 239 | Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes | 3.9 | 11 | Citations (PDF) |
| 240 | Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study | 11.4 | 66 | Citations (PDF) |
| 241 | Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials | 2.0 | 1 | Citations (PDF) |
| 242 | IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4+ T cells in rheumatoid arthritis | 6.0 | 12 | Citations (PDF) |
| 243 | Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis | 25.2 | 339 | Citations (PDF) |
| 244 | Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritis | 1.9 | 1 | Citations (PDF) |
| 245 | Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor | 2.3 | 2 | Citations (PDF) |
| 246 | Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis | 3.9 | 4 | Citations (PDF) |
| 247 | Systemic lupus erythematosus | 3.9 | 26 | Citations (PDF) |
| 248 | V．骨粗鬆症の薬物療法 | 0.0 | 0 | Citations (PDF) |
| 249 | Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments | 2.5 | 3 | Citations (PDF) |
| 250 | Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study | 1.9 | 30 | Citations (PDF) |
| 251 | Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders | 1.9 | 11 | Citations (PDF) |
| 252 | Case of autoimmune polyendocrine syndrome type 3 complicated with anti‐N‐methyl‐D‐aspartic acid‐receptor encephalitis | 2.7 | 2 | Citations (PDF) |
| 253 | A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate | 1.9 | 3 | Citations (PDF) |
| 254 | Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin‐2 Through Transcriptional Regulation in Systemic Lupus Erythematosus | 6.1 | 69 | Citations (PDF) |
| 255 | Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report | 0.9 | 5 | Citations (PDF) |
| 256 | Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study | 6.1 | 24 | Citations (PDF) |
| 257 | Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability | 3.4 | 32 | Citations (PDF) |
| 258 | A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years | 1.9 | 13 | Citations (PDF) |
| 259 | Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study | 1.9 | 18 | Citations (PDF) |
| 260 | Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report | 1.9 | 2 | Citations (PDF) |
| 261 | Associations between urinary 6‐sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes | 2.7 | 12 | Citations (PDF) |
| 262 | Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme | 6.9 | 206 | Citations (PDF) |
| 263 | The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | 1.9 | 87 | Citations (PDF) |
| 264 | Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials | 1.9 | 95 | Citations (PDF) |
| 265 | Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies | 1.9 | 17 | Citations (PDF) |
| 266 | Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study | 1.9 | 9 | Citations (PDF) |
| 267 | <i>SOD2</i> mRNA as a potential biomarker for exercise: interventional and cross-sectional research in healthy subjects | 1.4 | 11 | Citations (PDF) |
| 268 | Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study | 1.6 | 3 | Citations (PDF) |
| 269 | Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE) | 3.9 | 19 | Citations (PDF) |
| 270 | Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE) | 3.9 | 28 | Citations (PDF) |
| 271 | A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs | 1.9 | 23 | Citations (PDF) |
| 272 | European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance | 6.9 | 62 | Citations (PDF) |
| 273 | Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program | 2.8 | 41 | Citations (PDF) |
| 274 | Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry | 2.3 | 22 | Citations (PDF) |
| 275 | Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring | 3.4 | 10 | Citations (PDF) |
| 276 | The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus | 11.4 | 70 | Citations (PDF) |
| 277 | Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases | 3.9 | 27 | Citations (PDF) |
| 278 | Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis | 2.0 | 13 | Citations (PDF) |
| 279 | Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis | 1.9 | 9 | Citations (PDF) |
| 280 | Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview | 2.5 | 44 | Citations (PDF) |
| 281 | Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan | 2.0 | 25 | Citations (PDF) |
| 282 | Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis | 3.9 | 34 | Citations (PDF) |
| 283 | A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension | 0.9 | 7 | Citations (PDF) |
| 284 | Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting | 6.9 | 52 | Citations (PDF) |
| 285 | P134 Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with RA: results from RA-BEYOND | 1.9 | 0 | Citations (PDF) |
| 286 | Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study | 2.3 | 14 | Citations (PDF) |
| 287 | Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis | 0.8 | 7 | Citations (PDF) |
| 288 | Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study | 3.4 | 8 | Citations (PDF) |
| 289 | The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan | 2.8 | 25 | Citations (PDF) |
| 290 | Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report | 0.7 | 2 | Citations (PDF) |
| 291 | Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements | 1.6 | 25 | Citations (PDF) |
| 292 | Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic | 1.6 | 28 | Citations (PDF) |
| 293 | Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases | 6.0 | 30 | Citations (PDF) |
| 294 | Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study | 1.9 | 28 | Citations (PDF) |
| 295 | Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study | 3.9 | 14 | Citations (PDF) |
| 296 | Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea | 3.9 | 22 | Citations (PDF) |
| 297 | Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy | 1.5 | 9 | Citations (PDF) |
| 298 | Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis | 3.9 | 10 | Citations (PDF) |
| 299 | Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera | 6.6 | 21 | Citations (PDF) |
| 300 | Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus | 3.5 | 11 | Citations (PDF) |
| 301 | Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies | 1.1 | 9 | Citations (PDF) |
| 302 | Clinical relevance of T follicular helper cells in systemic lupus erythematosus | 3.5 | 28 | Citations (PDF) |
| 303 | Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review | 3.9 | 26 | Citations (PDF) |
| 304 | Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial | 6.9 | 228 | Citations (PDF) |
| 305 | Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study | 0.9 | 4 | Citations (PDF) |
| 306 | Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis | 2.0 | 7 | Citations (PDF) |
| 307 | Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study | 2.1 | 4 | Citations (PDF) |
| 308 | Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus | 4.2 | 3 | Citations (PDF) |
| 309 | T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease | 1.9 | 9 | Citations (PDF) |
| 310 | Rituximab in remission induction and maintenance therapy for microscopic polyangiitis associated with gastric cancer: A case report | 0.9 | 1 | Citations (PDF) |
| 311 | Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus | 3.9 | 23 | Citations (PDF) |
| 312 | Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials | 1.9 | 55 | Citations (PDF) |
| 313 | Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study | 1.9 | 27 | Citations (PDF) |
| 314 | Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study | 1.9 | 38 | Citations (PDF) |
| 315 | Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice | 1.2 | 7 | Citations (PDF) |
| 316 | Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial | 1.9 | 13 | Citations (PDF) |
| 317 | Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD | 1.9 | 8 | Citations (PDF) |
| 318 | The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method | 1.9 | 9 | Citations (PDF) |
| 319 | Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study | 1.9 | 6 | Citations (PDF) |
| 320 | Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA) | 1.9 | 26 | Citations (PDF) |
| 321 | Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan | 1.9 | 2 | Citations (PDF) |
| 322 | A case of systemic lupus erythematosus in which Cushing’s syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids | 0.9 | 1 | Citations (PDF) |
| 323 | Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study | 1.9 | 15 | Citations (PDF) |
| 324 | First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort | 6.9 | 26 | Citations (PDF) |
| 325 | An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma | 0.9 | 1 | Citations (PDF) |
| 326 | Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial | 6.9 | 21 | Citations (PDF) |
| 327 | Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials | 1.6 | 14 | Citations (PDF) |
| 328 | Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis | 3.5 | 9 | Citations (PDF) |
| 329 | Trial of Anifrolumab in Active Systemic Lupus Erythematosus | 34.5 | 1,265 | Citations (PDF) |
| 330 | 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study | 1.9 | 5 | Citations (PDF) |
| 331 | In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors | 1.9 | 29 | Citations (PDF) |
| 332 | Critical roles of super-enhancers in the pathogenesis of autoimmune diseases | 6.0 | 23 | Citations (PDF) |
| 333 | P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results | 1.9 | 1 | Citations (PDF) |
| 334 | <p>Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases</p> | 5.2 | 36 | Citations (PDF) |
| 335 | Su1862 POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 0.9 | 0 | Citations (PDF) |
| 336 | O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA | 1.9 | 0 | Citations (PDF) |
| 337 | Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction | 3.9 | 10 | Citations (PDF) |
| 338 | Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities | 6.9 | 46 | Citations (PDF) |
| 339 | Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory studyLupus, 2020, 29, 1902-1913 | 1.7 | 20 | Citations (PDF) |
| 340 | Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus | 3.4 | 6 | Citations (PDF) |
| 341 | Rheumatoid arthritis | 6.0 | 99 | Citations (PDF) |
| 342 | Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case reportLupus, 2020, 29, 1955-1960 | 1.7 | 8 | Citations (PDF) |
| 343 | A wide perspective of targeted therapies for precision medicine in autoimmune diseases | 0.8 | 9 | Citations (PDF) |
| 344 | Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study | 3.4 | 4 | Citations (PDF) |
| 345 | Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-γ Overproduction in T Helper 1 Cells | 4.9 | 26 | Citations (PDF) |
| 346 | Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme | 3.9 | 175 | Citations (PDF) |
| 347 | ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial | 3.9 | 16 | Citations (PDF) |
| 348 | Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis | 3.9 | 14 | Citations (PDF) |
| 349 | P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme | 1.9 | 2 | Citations (PDF) |
| 350 | Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients | 1.9 | 21 | Citations (PDF) |
| 351 | Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation | 3.9 | 15 | Citations (PDF) |
| 352 | Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report | 0.9 | 2 | Citations (PDF) |
| 353 | Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry | 3.9 | 34 | Citations (PDF) |
| 354 | State‐of‐the‐art treatment of systemic lupus erythematosus | 1.6 | 120 | Citations (PDF) |
| 355 | Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) | 1.9 | 26 | Citations (PDF) |
| 356 | Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan | 3.9 | 25 | Citations (PDF) |
| 357 | Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports | 0.9 | 1 | Citations (PDF) |
| 358 | Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study | 3.9 | 20 | Citations (PDF) |
| 359 | A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab | 0.9 | 7 | Citations (PDF) |
| 360 | A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease | 0.9 | 6 | Citations (PDF) |
| 361 | Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis | 1.6 | 21 | Citations (PDF) |
| 362 | Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening | 1.6 | 3 | Citations (PDF) |
| 363 | Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages | 3.9 | 29 | Citations (PDF) |
| 364 | Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study | 1.9 | 114 | Citations (PDF) |
| 365 | Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study | 1.9 | 4 | Citations (PDF) |
| 366 | Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis | 1.6 | 6 | Citations (PDF) |
| 367 | Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2 | 6.1 | 46 | Citations (PDF) |
| 368 | The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus | 1.6 | 13 | Citations (PDF) |
| 369 | Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials | 2.1 | 33 | Citations (PDF) |
| 370 | Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement | 0.8 | 15 | Citations (PDF) |
| 371 | Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study | 1.9 | 65 | Citations (PDF) |
| 372 | A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations | 0.0 | 0 | Citations (PDF) |
| 373 | The approach to precision medicine for the treatment of psoriatic arthritis | 2.5 | 8 | Citations (PDF) |
| 374 | Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions | 3.9 | 56 | Citations (PDF) |
| 375 | RANKL as a therapeutic target of rheumatoid arthritis | 1.9 | 46 | Citations (PDF) |
| 376 | Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study | 1.9 | 13 | Citations (PDF) |
| 377 | Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review | 4.1 | 39 | Citations (PDF) |
| 378 | Why remission is not enough: underlying disease mechanisms in RA that prevent cure | 25.5 | 82 | Citations (PDF) |
| 379 | Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators | 0.9 | 6 | Citations (PDF) |
| 380 | IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease | 0.8 | 6 | Citations (PDF) |
| 381 | P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis 2020, 5, | | 1 | Citations (PDF) |
| 382 | Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor | 0.8 | 1 | Citations (PDF) |
| 383 | Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial | 1.9 | 19 | Citations (PDF) |
| 384 | l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling | 1.9 | 33 | Citations (PDF) |
| 385 | Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study | 1.9 | 16 | Citations (PDF) |
| 386 | Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan | 1.9 | 7 | Citations (PDF) |
| 387 | 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus | 6.9 | 1,445 | Citations (PDF) |
| 388 | Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10 | 3.4 | 37 | Citations (PDF) |
| 389 | Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium–Glucose Cotransporter 2 Inhibitor | 4.6 | 2 | Citations (PDF) |
| 390 | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report | 0.4 | 12 | Citations (PDF) |
| 391 | The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis | 3.9 | 32 | Citations (PDF) |
| 392 | Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp<sup>+</sup>CD4<sup>+</sup> Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis | 0.8 | 1 | Citations (PDF) |
| 393 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan | 6.9 | 126 | Citations (PDF) |
| 394 | An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis | 0.8 | 6 | Citations (PDF) |
| 395 | Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study | 6.1 | 90 | Citations (PDF) |
| 396 | Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis | 3.3 | 14 | Citations (PDF) |
| 397 | Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis | 1.9 | 28 | Citations (PDF) |
| 398 | Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease | 3.9 | 18 | Citations (PDF) |
| 399 | Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis | 3.9 | 17 | Citations (PDF) |
| 400 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study | 62.1 | 352 | Citations (PDF) |
| 401 | A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis | 0.8 | 11 | Citations (PDF) |
| 402 | Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis | 6.9 | 25 | Citations (PDF) |
| 403 | Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰ | 3.8 | 20 | Citations (PDF) |
| 404 | Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update | 3.5 | 39 | Citations (PDF) |
| 405 | Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial | 6.9 | 140 | Citations (PDF) |
| 406 | Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan | 3.9 | 37 | Citations (PDF) |
| 407 | Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data | 1.6 | 15 | Citations (PDF) |
| 408 | Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine | 4.0 | 4 | Citations (PDF) |
| 409 | The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases? | 1.9 | 29 | Citations (PDF) |
| 410 | Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study | 2.9 | 4 | Citations (PDF) |
| 411 | IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2 | 3.4 | 106 | Citations (PDF) |
| 412 | Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia | 2.3 | 3 | Citations (PDF) |
| 413 | Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring | 3.4 | 4 | Citations (PDF) |
| 414 | Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance | 1.3 | 9 | Citations (PDF) |
| 415 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) | 6.9 | 110 | Citations (PDF) |
| 416 | Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy | 0.8 | 4 | Citations (PDF) |
| 417 | Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance | 1.9 | 24 | Citations (PDF) |
| 418 | Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus | 2.6 | 14 | Citations (PDF) |
| 419 | The front line of research into immunoglobin G4-related disease - Do autoantibodies cause immunoglobin G4-related disease? | 1.9 | 28 | Citations (PDF) |
| 420 | Scleroderma in an ice-cream shop worker | 1.9 | 3 | Citations (PDF) |
| 421 | Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies | 1.9 | 35 | Citations (PDF) |
| 422 | Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study | 1.9 | 21 | Citations (PDF) |
| 423 | Development of the Asia Pacific Lupus Collaboration cohort | 1.6 | 45 | Citations (PDF) |
| 424 | The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects | 0.9 | 2 | Citations (PDF) |
| 425 | Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus | 1.6 | 19 | Citations (PDF) |
| 426 | Immunophenotype involved in IgG4-related disease | 1.9 | 21 | Citations (PDF) |
| 427 | Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study | 1.9 | 13 | Citations (PDF) |
| 428 | Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept | 0.8 | 6 | Citations (PDF) |
| 429 | Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data | 1.9 | 17 | Citations (PDF) |
| 430 | Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T) | 1.9 | 6 | Citations (PDF) |
| 431 | Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping | 4.7 | 11 | Citations (PDF) |
| 432 | Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis | 1.9 | 108 | Citations (PDF) |
| 433 | 3) Recent Progress in Cytokine-targeting Therapies in Rheumatic Diseases | 0.0 | 0 | Citations (PDF) |
| 434 | Intracranial vessel wall lesions in patients with systematic lupus erythematosus | 3.4 | 19 | Citations (PDF) |
| 435 | Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching | 2.6 | 17 | Citations (PDF) |
| 436 | Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus | 1.9 | 65 | Citations (PDF) |
| 437 | Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis | 6.9 | 72 | Citations (PDF) |
| 438 | Clinical practice guideline for Sjögren’s syndrome 2017 | 1.9 | 60 | Citations (PDF) |
| 439 | Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study | 1.9 | 3 | Citations (PDF) |
| 440 | Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis:Post hocanalyses of overall and Japanese results from two phase 3 clinical trials | 1.9 | 17 | Citations (PDF) |
| 441 | Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials | 1.9 | 25 | Citations (PDF) |
| 442 | Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis | 3.6 | 17 | Citations (PDF) |
| 443 | Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease | 1.9 | 73 | Citations (PDF) |
| 444 | A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea | 6.9 | 288 | Citations (PDF) |
| 445 | Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring | 4.6 | 30 | Citations (PDF) |
| 446 | Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients | 3.9 | 18 | Citations (PDF) |
| 447 | Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system | 3.8 | 80 | Citations (PDF) |
| 448 | Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome | 2.6 | 61 | Citations (PDF) |
| 449 | JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial | 0.8 | 264 | Citations (PDF) |
| 450 | Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study | 1.9 | 36 | Citations (PDF) |
| 451 | Design characteristics of the Corrona Japan rheumatoid arthritis registry | 1.9 | 2 | Citations (PDF) |
| 452 | Twenty‐four‐hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring | 2.7 | 12 | Citations (PDF) |
| 453 | Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis | 1.9 | 85 | Citations (PDF) |
| 454 | A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period | 1.9 | 18 | Citations (PDF) |
| 455 | Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis | 1.9 | 58 | Citations (PDF) |
| 456 | Relevance of P-glycoprotein on CXCR4+B cells to organ manifestation in highly active rheumatoid arthritis | 1.9 | 17 | Citations (PDF) |
| 457 | Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study | 1.9 | 6 | Citations (PDF) |
| 458 | Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients | 2.7 | 11 | Citations (PDF) |
| 459 | RANKL: A therapeutic target for bone destruction in rheumatoid arthritis | 1.9 | 74 | Citations (PDF) |
| 460 | Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120 | 1.9 | 7 | Citations (PDF) |
| 461 | Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) | 6.9 | 360 | Citations (PDF) |
| 462 | Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC) | 1.9 | 18 | Citations (PDF) |
| 463 | Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials | 1.9 | 43 | Citations (PDF) |
| 464 | B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus | 2.6 | 46 | Citations (PDF) |
| 465 | The role of nailfold videocapillaroscopy in patients with systemic sclerosis | 2.5 | 11 | Citations (PDF) |
| 466 | Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells | 0.6 | 6 | Citations (PDF) |
| 467 | Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study | 3.9 | 12 | Citations (PDF) |
| 468 | Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis | 4.9 | 73 | Citations (PDF) |
| 469 | The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy | 0.8 | 12 | Citations (PDF) |
| 470 | Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial | 6.9 | 175 | Citations (PDF) |
| 471 | Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis | 3.9 | 62 | Citations (PDF) |
| 472 | Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus | 4.9 | 103 | Citations (PDF) |
| 473 | Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study | 1.6 | 49 | Citations (PDF) |
| 474 | Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance | 0.8 | 1 | Citations (PDF) |
| 475 | IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion | 0.8 | 25 | Citations (PDF) |
| 476 | Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension | 0.8 | 4 | Citations (PDF) |
| 477 | Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study) | 6.9 | 48 | Citations (PDF) |
| 478 | Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis | 6.1 | 37 | Citations (PDF) |
| 479 | Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System | 4.9 | 132 | Citations (PDF) |
| 480 | Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study | 3.4 | 69 | Citations (PDF) |
| 481 | Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition | 2.6 | 84 | Citations (PDF) |
| 482 | Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial | 62.1 | 483 | Citations (PDF) |
| 483 | Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study | 3.9 | 15 | Citations (PDF) |
| 484 | Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair | 6.0 | 43 | Citations (PDF) |
| 485 | Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs | 2.8 | 3 | Citations (PDF) |
| 486 | Hyperparathyroidism-jaw Tumor Syndrome Confirmed by Preoperative Genetic Testing | 0.8 | 11 | Citations (PDF) |
| 487 | Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring | 4.6 | 34 | Citations (PDF) |
| 488 | Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors | 6.9 | 87 | Citations (PDF) |
| 489 | Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus | 0.9 | 1 | Citations (PDF) |
| 490 | Clinical immunity in bone and joints | 1.9 | 68 | Citations (PDF) |
| 491 | Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study | 3.3 | 23 | Citations (PDF) |
| 492 | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials | 6.9 | 374 | Citations (PDF) |
| 493 | Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial | 6.9 | 46 | Citations (PDF) |
| 494 | Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study | 62.1 | 104 | Citations (PDF) |
| 495 | Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis | 34.5 | 879 | Citations (PDF) |
| 496 | Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study | 1.9 | 19 | Citations (PDF) |
| 497 | Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients | 6.1 | 102 | Citations (PDF) |
| 498 | The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases | 0.9 | 1 | Citations (PDF) |
| 499 | Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study | 3.9 | 16 | Citations (PDF) |
| 500 | Determinants of hemoglobin A1c level in patients with type 2 diabetes after in‐hospital diabetes education: A study based on continuous glucose monitoring | 2.7 | 11 | Citations (PDF) |
| 501 | Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus | 3.4 | 38 | Citations (PDF) |
| 502 | Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy | 6.1 | 222 | Citations (PDF) |
| 503 | Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis | 1.2 | 4 | Citations (PDF) |
| 504 | Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells | 4.4 | 22 | Citations (PDF) |
| 505 | Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study | 6.9 | 104 | Citations (PDF) |
| 506 | A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand | 0.9 | 4 | Citations (PDF) |
| 507 | Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head | 3.4 | 32 | Citations (PDF) |
| 508 | A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease | 1.9 | 90 | Citations (PDF) |
| 509 | Factors influencing inter‐day glycemic variability in diabetic outpatients receiving insulin therapy | 2.7 | 26 | Citations (PDF) |
| 510 | Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study | 1.9 | 8 | Citations (PDF) |
| 511 | Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab | 1.9 | 57 | Citations (PDF) |
| 512 | Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study | 1.9 | 27 | Citations (PDF) |
| 513 | Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy | 3.9 | 11 | Citations (PDF) |
| 514 | The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus | 0.8 | 16 | Citations (PDF) |
| 515 | Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring | 3.4 | 13 | Citations (PDF) |
| 516 | Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus | 1.6 | 7 | Citations (PDF) |
| 517 | Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis | 0.8 | 2 | Citations (PDF) |
| 518 | A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically | 1.7 | 0 | Citations (PDF) |
| 519 | Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels | 0.8 | 19 | Citations (PDF) |
| 520 | Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease | 2.3 | 31 | Citations (PDF) |
| 521 | Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus | 0.8 | 18 | Citations (PDF) |
| 522 | Two Sisters with Graves' Disease and Similar Clinical Features who Tested Positive for Anti-insulin Antibodies after Thiamazole Treatment | 0.8 | 8 | Citations (PDF) |
| 523 | The changing landscape of biosimilars in rheumatology | 6.9 | 178 | Citations (PDF) |
| 524 | Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study) | 6.9 | 98 | Citations (PDF) |
| 525 | Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study | 3.9 | 26 | Citations (PDF) |
| 526 | Usefulness of nailfold videocapillaroscopy for systemic sclerosis | 6.0 | 10 | Citations (PDF) |
| 527 | Thin-section chest CT findings in polymyalgia rheumatica: a comparison between with and without rheumatoid arthritis | 1.3 | 8 | Citations (PDF) |
| 528 | Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial | 6.9 | 172 | Citations (PDF) |
| 529 | Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions | 6.9 | 279 | Citations (PDF) |
| 530 | Chemical JAK inhibitors for the treatment of rheumatoid arthritis | 2.1 | 25 | Citations (PDF) |
| 531 | Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial | 1.9 | 47 | Citations (PDF) |
| 532 | Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies | 1.6 | 30 | Citations (PDF) |
| 533 | Prediction of Femoral Neck Strength in Patients with Diabetes Mellitus with Trabecular Bone Analysis and Tomosynthesis Images | 8.7 | 17 | Citations (PDF) |
| 534 | Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis | 6.2 | 58 | Citations (PDF) |
| 535 | Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis | 1.9 | 23 | Citations (PDF) |
| 536 | Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes | 1.6 | 15 | Citations (PDF) |
| 537 | BAFF- and APRIL-targeted therapy in systemic autoimmune diseases | 6.0 | 67 | Citations (PDF) |
| 538 | Baricitinib for the treatment of rheumatoid arthritis | 3.5 | 37 | Citations (PDF) |
| 539 | T follicular helper (Tfh) cells in autoimmune diseases | 0.6 | 9 | Citations (PDF) |
| 540 | Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score | 0.6 | 10 | Citations (PDF) |
| 541 | Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study | 1.9 | 27 | Citations (PDF) |
| 542 | Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis | 1.9 | 0 | Citations (PDF) |
| 543 | Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study | 3.9 | 142 | Citations (PDF) |
| 544 | B-cell subsets, signaling and their roles in secretion of autoantibodies | 1.7 | 72 | Citations (PDF) |
| 545 | Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis | 3.5 | 41 | Citations (PDF) |
| 546 | Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis | 1.9 | 96 | Citations (PDF) |
| 547 | Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome | 1.9 | 35 | Citations (PDF) |
| 548 | Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study | 6.9 | 144 | Citations (PDF) |
| 549 | Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study | 1.9 | 17 | Citations (PDF) |
| 550 | Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial | 1.9 | 60 | Citations (PDF) |
| 551 | Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study | 2.3 | 121 | Citations (PDF) |
| 552 | Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis | 2.7 | 10 | Citations (PDF) |
| 553 | Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study | 0.9 | 10 | Citations (PDF) |
| 554 | Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice | 1.9 | 14 | Citations (PDF) |
| 555 | <i><b>Post-hoc</b></i> analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis | 1.9 | 10 | Citations (PDF) |
| 556 | Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab | 1.9 | 8 | Citations (PDF) |
| 557 | Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study | 1.9 | 28 | Citations (PDF) |
| 558 | Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching | 6.9 | 46 | Citations (PDF) |
| 559 | The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression | 6.9 | 110 | Citations (PDF) |
| 560 | Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial | 1.9 | 15 | Citations (PDF) |
| 561 | Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study | 1.9 | 7 | Citations (PDF) |
| 562 | Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy | 1.9 | 49 | Citations (PDF) |
| 563 | Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold | 2.3 | 53 | Citations (PDF) |
| 564 | Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves&rsquo; disease and type 1 diabetes mellitus: A case report | 1.6 | 5 | Citations (PDF) |
| 565 | Incidence of Vitamin D Deficiency and Its Relevance to Bone Metabolism in Japanese Postmenopausal Women with Type 2 Diabetes Mellitus | 0.8 | 9 | Citations (PDF) |
| 566 | A Case of Gravesʼ Disease with Remarkable Psychiatric Symptoms | 1.7 | 2 | Citations (PDF) |
| 567 | Abnormal expression of chemokine receptor on B cells in patients with SLE | 0.6 | 1 | Citations (PDF) |
| 568 | A multi-biomarker disease activity score for monitoring rheumatoid arthritis | 0.1 | 3 | Citations (PDF) |
| 569 | Secondary Adrenocortical Insufficiency Complicated by Marked Hypercalcemia and Eosinophilia: A Case Report | 1.7 | 1 | Citations (PDF) |
| 570 | Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis | 1.7 | 46 | Citations (PDF) |
| 571 | Histamine inhibits differentiation of skin fibroblasts into myofibroblasts | 2.1 | 20 | Citations (PDF) |
| 572 | Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies | 1.9 | 12 | Citations (PDF) |
| 573 | Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry | 3.9 | 65 | Citations (PDF) |
| 574 | Combination therapy for early rheumatoid arthritis: a treatment holiday perspective | 2.5 | 4 | Citations (PDF) |
| 575 | Contribution of the Interleukin‐6/STAT‐3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells | 6.1 | 103 | Citations (PDF) |
| 576 | Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan | 1.9 | 19 | Citations (PDF) |
| 577 | Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis | 1.9 | 77 | Citations (PDF) |
| 578 | A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study | 1.9 | 19 | Citations (PDF) |
| 579 | Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study | 1.9 | 128 | Citations (PDF) |
| 580 | Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy | 6.1 | 69 | Citations (PDF) |
| 581 | Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus | 1.7 | 44 | Citations (PDF) |
| 582 | Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside | 1.5 | 70 | Citations (PDF) |
| 583 | Relevance of lymphocyte subsets to B cell‐targeted therapy in systemic lupus erythematosus | 1.6 | 25 | Citations (PDF) |
| 584 | Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus | 9.4 | 40 | Citations (PDF) |
| 585 | Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks | 1.9 | 37 | Citations (PDF) |
| 586 | Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation | 1.9 | 44 | Citations (PDF) |
| 587 | Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study | 2.3 | 44 | Citations (PDF) |
| 588 | Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study | 2.3 | 9 | Citations (PDF) |
| 589 | Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab | 3.9 | 45 | Citations (PDF) |
| 590 | Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis:<i>post hoc</i>time-course analysis of an all-case PMS in Japan | 1.9 | 5 | Citations (PDF) |
| 591 | Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study | 6.9 | 167 | Citations (PDF) |
| 592 | Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus | 1.9 | 72 | Citations (PDF) |
| 593 | Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study | 1.9 | 37 | Citations (PDF) |
| 594 | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan | 1.9 | 40 | Citations (PDF) |
| 595 | Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study) | 2.0 | 3 | Citations (PDF) |
| 596 | Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study | 1.9 | 15 | Citations (PDF) |
| 597 | Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia | 3.6 | 22 | Citations (PDF) |
| 598 | Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats | 2.3 | 22 | Citations (PDF) |
| 599 | HIV-associated nephropathy with amoebic enteritis: a case report and literature review | 0.3 | 0 | Citations (PDF) |
| 600 | An Approach to Bone and Cartilage Repair of Rheumatoid Arthritis by Mesenchymal Stem Cells | 1.7 | 7 | Citations (PDF) |
| 601 | The possible mode of action of Tofacitinib, a JAK inhibitor | 6.0 | 1 | Citations (PDF) |
| 602 | Apathetic Hyperthyroidism with Heart Failure in an Elderly Patient with Plummerʼs Disease | 1.7 | 0 | Citations (PDF) |
| 603 | A Case of Parathyroid Carcinoma with a Highly Aggressive Clinical Course | 1.7 | 3 | Citations (PDF) |
| 604 | Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT) | 4.0 | 165 | Citations (PDF) |
| 605 | Efficacy and safety of reducing duration of infliximab infusion | 1.9 | 4 | Citations (PDF) |
| 606 | Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial | 1.9 | 49 | Citations (PDF) |
| 607 | Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis | 1.9 | 36 | Citations (PDF) |
| 608 | Acquiring Chondrocyte Phenotype from Human Mesenchymal Stem Cells under Inflammatory Conditions | 4.4 | 31 | Citations (PDF) |
| 609 | Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors | 1.9 | 16 | Citations (PDF) |
| 610 | Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan | 2.3 | 202 | Citations (PDF) |
| 611 | Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients | 1.9 | 106 | Citations (PDF) |
| 612 | Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro | 6.9 | 47 | Citations (PDF) |
| 613 | Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid ArthritisDrugs, 2014, 74, 2129-2139 | 11.4 | 17 | Citations (PDF) |
| 614 | Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes | 9.4 | 20 | Citations (PDF) |
| 615 | Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study | 1.9 | 11 | Citations (PDF) |
| 616 | Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study | 1.9 | 12 | Citations (PDF) |
| 617 | Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial | 1.9 | 27 | Citations (PDF) |
| 618 | Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial | 1.9 | 56 | Citations (PDF) |
| 619 | Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events | 1.9 | 47 | Citations (PDF) |
| 620 | A case of teriparatide-induced severe hypophosphatemia and hypercalcemia | 1.9 | 17 | Citations (PDF) |
| 621 | IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent | 1.9 | 59 | Citations (PDF) |
| 622 | Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus | 2.7 | 98 | Citations (PDF) |
| 623 | Pterostilbene surpassed resveratrol for anti-inflammatory application: Potency consideration and pharmacokinetics perspective | 3.6 | 80 | Citations (PDF) |
| 624 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study | 6.9 | 94 | Citations (PDF) |
| 625 | Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update | 1.9 | 176 | Citations (PDF) |
| 626 | Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study | 3.9 | 70 | Citations (PDF) |
| 627 | Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia<sup>®</sup>as Biological Intensive Treatment for RA (ORBIT) study | 1.9 | 16 | Citations (PDF) |
| 628 | Systemic Lupus Erythematosus | 2.7 | 2 | Citations (PDF) |
| 629 | The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells | 6.9 | 167 | Citations (PDF) |
| 630 | Tomosynthesis of the Wrist and Hand in Patients With Rheumatoid Arthritis: Comparison With Radiography and MRI | 4.1 | 46 | Citations (PDF) |
| 631 | The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database | 2.4 | 15 | Citations (PDF) |
| 632 | Glucose variability before and after treatment of a patient with Graves’ disease complicated by diabetes mellitus: Assessment by continuous glucose monitoring | 1.6 | 9 | Citations (PDF) |
| 633 | Type 2 Diabetes Mellitus Complicated by Hypertension in Japanese Patients: Switching Treatment from High-dose Angiotensin II Receptor Blockers to Losartan Plus Hydrochlorothiazide | 0.8 | 5 | Citations (PDF) |
| 634 | The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism | 6.0 | 2 | Citations (PDF) |
| 635 | Dopamine D2-like receptor signaling suppresses human osteoclastogenesis | 3.4 | 63 | Citations (PDF) |
| 636 | Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis? | 2.7 | 23 | Citations (PDF) |
| 637 | The Histone Deacetylase Inhibitors MS-275 and SAHA Suppress the p38 Mitogen-Activated Protein Kinase Signaling Pathway and Chemotaxis in Rheumatoid Arthritic Synovial Fibroblastic E11 Cells | 4.2 | 28 | Citations (PDF) |
| 638 | Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study | 3.9 | 45 | Citations (PDF) |
| 639 | Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes | 3.8 | 47 | Citations (PDF) |
| 640 | Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren’s syndrome | 1.9 | 5 | Citations (PDF) |
| 641 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study | 6.1 | 536 | Citations (PDF) |
| 642 | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring | 2.7 | 14 | Citations (PDF) |
| 643 | A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study | 1.9 | 86 | Citations (PDF) |
| 644 | Diagnosis of early-stage rheumatoid arthritis: usefulness of unenhanced and gadolinium-enhanced MR images at 3 T | 1.3 | 12 | Citations (PDF) |
| 645 | Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus | 9.4 | 242 | Citations (PDF) |
| 646 | Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia | 0.9 | 6 | Citations (PDF) |
| 647 | Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study | 1.9 | 0 | Citations (PDF) |
| 648 | Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? | 6.9 | 46 | Citations (PDF) |
| 649 | Janus kinase inhibitors in autoimmune diseases | 6.9 | 422 | Citations (PDF) |
| 650 | Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study | 1.9 | 8 | Citations (PDF) |
| 651 | No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan | 1.9 | 22 | Citations (PDF) |
| 652 | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks | 6.9 | 56 | Citations (PDF) |
| 653 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions | 6.9 | 111 | Citations (PDF) |
| 654 | Clinical characteristics and risk factors forPneumocystis jiroveciipneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients | 1.9 | 30 | Citations (PDF) |
| 655 | Safety and Effectiveness of 6 Months’ Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs | 2.3 | 14 | Citations (PDF) |
| 656 | Validation of different sets of criteria for the diagnosis of Sjögren’s syndrome in Japanese patients | 1.9 | 23 | Citations (PDF) |
| 657 | Activation of Wnt5a‐Ror2 signaling associated with epithelial‐to‐mesenchymal transition of tubular epithelial cells during renal fibrosis | 1.4 | 42 | Citations (PDF) |
| 658 | JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical | 1.9 | 57 | Citations (PDF) |
| 659 | Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension | 1.6 | 15 | Citations (PDF) |
| 660 | Extrapyramidal Symptoms and Advanced Calcification of the Basal Ganglia in a Patient with Autosomal Dominant Hypocalcemia | 0.8 | 12 | Citations (PDF) |
| 661 | Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis | 1.9 | 18 | Citations (PDF) |
| 662 | Juvenile-onset Hereditary Pheochromocytoma-paraganglioma Syndrome | 0.8 | 2 | Citations (PDF) |
| 663 | Regulation of Osteoclastogenesis by Human Mesenchymal Stem Cells Leading to Application of a Novel Treatment for Rheumatoid Arthritis | 1.7 | 4 | Citations (PDF) |
| 664 | Dopamine receptor signaling regulates human osteoclastogenesis | 0.6 | 9 | Citations (PDF) |
| 665 | IL-17 Inhibits Chondrogenic Differentiation of Human Mesenchymal Stem Cells | 2.3 | 49 | Citations (PDF) |
| 666 | Iatrogenic Osteomalacia: Report of Two Cases | 1.7 | 11 | Citations (PDF) |
| 667 | JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical | 1.9 | 30 | Citations (PDF) |
| 668 | 4. Drugs Targeting Intracellular Molecule: JAK Inhibitor and Syk Inhibitor | 0.1 | 0 | Citations (PDF) |
| 669 | Regulatory role of mesenchymal stem cells in osteoclast differentiation | 6.0 | 1 | Citations (PDF) |
| 670 | Role of JAKs in myeloid cells and autoimmune diseases | 6.0 | 0 | Citations (PDF) |
| 671 | A Case of Multiple Endocrine Neoplasia 2B with Probable Ectopic Adrenocorticotropic Hormone-Secreting Liver Metastasis from Medullary Thyroid Carcinoma | 1.7 | 4 | Citations (PDF) |
| 672 | Effect of Metformin in Elderly Type 2 Diabetes | 1.7 | 0 | Citations (PDF) |
| 673 | Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy | 6.9 | 14 | Citations (PDF) |
| 674 | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study | 6.9 | 106 | Citations (PDF) |
| 675 | Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study | 2.3 | 26 | Citations (PDF) |
| 676 | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | 1.9 | 39 | Citations (PDF) |
| 677 | Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules | 6.9 | 54 | Citations (PDF) |
| 678 | Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 | 1.9 | 1,440 | Citations (PDF) |
| 679 | B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE | 6.9 | 14 | Citations (PDF) |
| 680 | Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis | 3.6 | 44 | Citations (PDF) |
| 681 | A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details | 1.9 | 741 | Citations (PDF) |
| 682 | Involvement of Syk in pathology of systemic autoimmune disease | 0.6 | 6 | Citations (PDF) |
| 683 | A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies | 1.9 | 5 | Citations (PDF) |
| 684 | Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHDBlood, 2012, 119, 5575-5583 | 5.0 | 47 | Citations (PDF) |
| 685 | A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome | 1.6 | 20 | Citations (PDF) |
| 686 | Fibroblast Growth Factor 23-Related Osteomalacia Caused by the Prolonged Administration of Saccharated Ferric Oxide | 0.8 | 33 | Citations (PDF) |
| 687 | Pneumocystis jiroveciipneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors | 1.9 | 52 | Citations (PDF) |
| 688 | Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients | 1.9 | 84 | Citations (PDF) |
| 689 | Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial | 1.9 | 75 | Citations (PDF) |
| 690 | Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity | 1.9 | 32 | Citations (PDF) |
| 691 | Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept | 1.9 | 6 | Citations (PDF) |
| 692 | A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies | 1.9 | 2 | Citations (PDF) |
| 693 | Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients | 1.9 | 19 | Citations (PDF) |
| 694 | Thin-section chest CT findings in systemic lupus erythematosus with antiphospholipid syndrome: A comparison with systemic lupus erythematosus without antiphospholipid syndrome | 2.8 | 13 | Citations (PDF) |
| 695 | Interleukin‐1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt‐5a/receptor tyrosine kinase–like orphan receptor 2 pathway | 6.1 | 147 | Citations (PDF) |
| 696 | Amplification of Toll-like receptor–mediated signaling through spleen tyrosine kinase in human B-cell activation | 6.1 | 47 | Citations (PDF) |
| 697 | Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients | 3.3 | 31 | Citations (PDF) |
| 698 | Regulation of inflammation through JAK3-Stat6 pathway in dendritic cells | 0.6 | 3 | Citations (PDF) |
| 699 | A Case of Postural Orthostatic Tachycardia Syndrome (POTS) with Difficulties in Differentiation from Hypoglycemic Attack | 1.7 | 0 | Citations (PDF) |
| 700 | Anti-rheumatic effect of JAK-inhibitors | 0.6 | 2 | Citations (PDF) |
| 701 | Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis | 2.8 | 81 | Citations (PDF) |
| 702 | The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells | 6.1 | 224 | Citations (PDF) |
| 703 | Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally | 2.3 | 5 | Citations (PDF) |
| 704 | Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes | 1.9 | 16 | Citations (PDF) |
| 705 | A case of multiple brown tumors with primary hyperparathyroidism | 1.9 | 16 | Citations (PDF) |
| 706 | A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details | 1.9 | 469 | Citations (PDF) |
| 707 | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | 1.9 | 26 | Citations (PDF) |
| 708 | Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial | 1.9 | 30 | Citations (PDF) |
| 709 | Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients | 1.9 | 47 | Citations (PDF) |
| 710 | Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 | 1.9 | 1,015 | Citations (PDF) |
| 711 | Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity | 1.9 | 21 | Citations (PDF) |
| 712 | Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis | 1.9 | 8 | Citations (PDF) |
| 713 | Mutual Interaction Between Vitamin D and Lifestyle-Related Diseases in Women | 1.7 | 1 | Citations (PDF) |
| 714 | Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis | 6.0 | 1 | Citations (PDF) |
| 715 | Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren’s syndrome | 1.9 | 3 | Citations (PDF) |
| 716 | Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study | 1.9 | 3 | Citations (PDF) |
| 717 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study) | 1.9 | 70 | Citations (PDF) |
| 718 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis | 1.9 | 102 | Citations (PDF) |
| 719 | Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety | 2.3 | 151 | Citations (PDF) |
| 720 | Recent progress in small molecular products for the treatment of joint and bone diseases: an over view | 6.0 | 0 | Citations (PDF) |
| 721 | JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug | 6.0 | 1 | Citations (PDF) |
| 722 | Evaluation of Intestinal Microbiotas of Healthy Japanese Adults and Effect of Antibiotics Using the 16S Ribosomal RNA Gene Based Clone Library Method | 1.5 | 30 | Citations (PDF) |
| 723 | Cytokine-mediated signals as targets for treatment of rheumatoid arthritis: a JAK inhibitorin vitroandin vivo | 0.4 | 0 | Citations (PDF) |
| 724 | Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate | 2.8 | 281 | Citations (PDF) |
| 725 | Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production | 6.1 | 84 | Citations (PDF) |
| 726 | Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients | 6.9 | 185 | Citations (PDF) |
| 727 | Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab | 2.3 | 67 | Citations (PDF) |
| 728 | Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study | 2.3 | 77 | Citations (PDF) |
| 729 | Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease | 1.9 | 72 | Citations (PDF) |
| 730 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial | 1.9 | 22 | Citations (PDF) |
| 731 | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study | 1.9 | 80 | Citations (PDF) |
| 732 | The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis | 1.9 | 16 | Citations (PDF) |
| 733 | Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy | 1.9 | 17 | Citations (PDF) |
| 734 | Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease | 1.3 | 26 | Citations (PDF) |
| 735 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study) | 1.9 | 53 | Citations (PDF) |
| 736 | Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease | 1.9 | 51 | Citations (PDF) |
| 737 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis | 1.9 | 52 | Citations (PDF) |
| 738 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial | 1.9 | 16 | Citations (PDF) |
| 739 | Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases | 6.0 | 6 | Citations (PDF) |
| 740 | Denosumab for the treatment of joint and bone diseases | 6.0 | 1 | Citations (PDF) |
| 741 | Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept | 1.9 | 2 | Citations (PDF) |
| 742 | Achieving drug-free remission: elucidating the role of TNF in rheumatoid arthritisinhibitors | 0.4 | 0 | Citations (PDF) |
| 743 | A Case of AA Amyloidosis Associated with Rheumatoid Arthritis Successfully Treated with Anti IL-6 Receptor Antibody Tocilizumab. | 0.0 | 0 | Citations (PDF) |
| 744 | Differential Diagnosis of Rheumatoid Arthritis. | 0.0 | 0 | Citations (PDF) |
| 745 | Involvement of mast cells in systemic sclerosis | 0.6 | 7 | Citations (PDF) |
| 746 | C5a promotes migration, proliferation, and vessel formation in endothelial cells | 4.8 | 54 | Citations (PDF) |
| 747 | Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway | 2.7 | 116 | Citations (PDF) |
| 748 | Mast cell–derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho‐mediated signaling | 6.1 | 48 | Citations (PDF) |
| 749 | Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis | 1.9 | 20 | Citations (PDF) |
| 750 | Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis | 2.3 | 60 | Citations (PDF) |
| 751 | Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus | 4.1 | 19 | Citations (PDF) |
| 752 | Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study | 6.9 | 264 | Citations (PDF) |
| 753 | Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial | 1.9 | 63 | Citations (PDF) |
| 754 | Curdlan Induces DC-Mediated Th17 Polarization via Jagged1 Activation in Human Dendritic Cells | 4.7 | 49 | Citations (PDF) |
| 755 | Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF- B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells | 1.9 | 115 | Citations (PDF) |
| 756 | Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway | 2.1 | 58 | Citations (PDF) |
| 757 | Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis | 1.9 | 10 | Citations (PDF) |
| 758 | Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial | 1.9 | 44 | Citations (PDF) |
| 759 | Dopamine as an immune-modulator between dendritic cells and T cells and the role of dopamine in the pathogenesis of Rheumatoid Arthritis | 0.6 | 13 | Citations (PDF) |
| 760 | Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drug | 0.6 | 13 | Citations (PDF) |
| 761 | Effects of anti-TNF- antibody infliximab in refractory entero-Behcet's disease | 1.9 | 51 | Citations (PDF) |
| 762 | Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan | 2.3 | 172 | Citations (PDF) |
| 763 | Dopamine released by dendritic cells polarizes Th2 differentiation | 3.1 | 125 | Citations (PDF) |
| 764 | Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy | 1.9 | 20 | Citations (PDF) |
| 765 | B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases | 0.2 | 2 | Citations (PDF) |
| 766 | New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis | 0.6 | 2 | Citations (PDF) |
| 767 | Interaction of Galectin-9 With Lipid Rafts Induces Osteoblast Proliferation Through the c-Src/ERK Signaling Pathway | 4.9 | 40 | Citations (PDF) |
| 768 | Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis | 2.1 | 142 | Citations (PDF) |
| 769 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) | 1.9 | 65 | Citations (PDF) |
| 770 | Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission | 1.9 | 45 | Citations (PDF) |
| 771 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) | 1.9 | 41 | Citations (PDF) |
| 772 | Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy | 2.3 | 54 | Citations (PDF) |
| 773 | Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase | 2.2 | 55 | Citations (PDF) |
| 774 | Evaluation of Adjuvant Activities Using Human Antigen Presenting Cells in Vitro | 4.7 | 12 | Citations (PDF) |
| 775 | Reply to Dr Pollono | 1.6 | 0 | Citations (PDF) |
| 776 | Complete Resolution of Dermatomyositis with Refractory Cutaneous Vasculitis by Intravenous Cyclophosphamide Pulse Therapy | 0.8 | 26 | Citations (PDF) |
| 777 | Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody | 1.6 | 71 | Citations (PDF) |
| 778 | Boan and Joint Disease Internal Medicine Specialist Provide Medical Care; New Evolutiion of the Treatment. Expectations of Primary Care Physicians | 0.0 | 0 | Citations (PDF) |
| 779 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) | 1.9 | 44 | Citations (PDF) |
| 780 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) | 1.9 | 29 | Citations (PDF) |
| 781 | Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission | 1.9 | 32 | Citations (PDF) |
| 782 | Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis | 1.9 | 15 | Citations (PDF) |
| 783 | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | 1.9 | 109 | Citations (PDF) |
| 784 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) | 1.9 | 57 | Citations (PDF) |
| 785 | Erythropoietin resistant anemia and neutropenia due to copper deficiency during long-term enteral nutrition on maintained hemodialysis. | 0.0 | 1 | Citations (PDF) |
| 786 | Treatment of Inflammatory Immunologic Disease 4. B Cell Targeting Therapy Using the Anti-CD20 Antibody Rituximab in Inflammatory Autoimmune Diseases | 0.8 | 18 | Citations (PDF) |
| 787 | Low Molecular Weight Hyaluronan Increases the Uptaking of Oxidized LDL into Monocytes | 1.6 | 14 | Citations (PDF) |
| 788 | Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial | 1.9 | 35 | Citations (PDF) |
| 789 | Small GTPase Rho signaling is involved in β1 integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor κB ligand on osteoblasts and osteoclast maturation | 2.1 | 14 | Citations (PDF) |
| 790 | A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate | 1.9 | 10 | Citations (PDF) |
| 791 | Activation signal transduction by β1 integrin in T cells from patients with systemic lupus erythematosus | 6.1 | 29 | Citations (PDF) |
| 792 | Constitutive association of MyD88 to IRAK in HTLV-I–transformed T cells | 0.4 | 8 | Citations (PDF) |
| 793 | A case of blue rubber bleb nevus syndrome treated by etidronate | 1.9 | 4 | Citations (PDF) |
| 794 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) | 1.9 | 47 | Citations (PDF) |
| 795 | A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate | 1.9 | 10 | Citations (PDF) |
| 796 | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | 1.9 | 92 | Citations (PDF) |
| 797 | Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial | 1.9 | 24 | Citations (PDF) |
| 798 | Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis | 1.9 | 11 | Citations (PDF) |
| 799 | Lansoprazole-Induced Improvement of Esophageal Submucosal Injury | 1.4 | 4 | Citations (PDF) |
| 800 | Activation of the Inflammatory Cytokine Genes by Intracellular Galectin-9 in Human Monocytes.Blood, 2007, 110, 2212-2212 | 5.0 | 0 | Citations (PDF) |
| 801 | Acetylation of an Ets Transcription Factor PU.1 Suppresses Its Transcriptional Activity.Blood, 2007, 110, 2402-2402 | 5.0 | 0 | Citations (PDF) |
| 802 | Abnormal intracellular distribution of NFAT1 in T lymphocytes from patients with systemic lupus erythematosus and characteristic clinical features | 2.6 | 15 | Citations (PDF) |
| 803 | Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes | 2.1 | 16 | Citations (PDF) |
| 804 | Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus | 2.1 | 72 | Citations (PDF) |
| 805 | A Rare Case of Adult-onset Nesidioblastosis Treated Successfully with Diazoxide | 1.6 | 30 | Citations (PDF) |
| 806 | Serum Hyaluronan Concentration as a Marker of Angiopathy in Patients with Diabetes Mellitus | 1.6 | 37 | Citations (PDF) |
| 807 | Benign Symmetric Lipomatosis Associated with Alcoholism | 0.8 | 24 | Citations (PDF) |
| 808 | Successful Treatment of Insulinoma by a Single Daily Dose of Octreotide in Two Elderly Female Patients | 1.6 | 19 | Citations (PDF) |
| 809 | Anti-CD20 and other novel biotherapies for systemic lupus erythematosus | 0.3 | 3 | Citations (PDF) |
| 810 | Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125 | 1.4 | 12 | Citations (PDF) |
| 811 | Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients | 7.1 | 16 | Citations (PDF) |
| 812 | Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells | 2.2 | 20 | Citations (PDF) |
| 813 | Engagement of CD44 up-regulates Fas Ligand expression on T cells leading to activation-induced cell death | 7.0 | 33 | Citations (PDF) |
| 814 | Multi-drug resistance in the treatments of autoimmune diseases | 0.6 | 8 | Citations (PDF) |
| 815 | Acro-Osteolysis and Symphalangism Mutations | 4.9 | 1 | Citations (PDF) |
| 816 | Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease | 1.9 | 5 | Citations (PDF) |
| 817 | Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus | 6.1 | 86 | Citations (PDF) |
| 818 | Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus | 1.9 | 15 | Citations (PDF) |
| 819 | Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management | 1.9 | 9 | Citations (PDF) |
| 820 | Title is missing! | 4.3 | 20 | Citations (PDF) |
| 821 | Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus | 1.9 | 16 | Citations (PDF) |
| 822 | Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management | 1.9 | 6 | Citations (PDF) |
| 823 | Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease | 1.9 | 6 | Citations (PDF) |
| 824 | Adult-Onset Idiopathic Progressive Acro-Osteolysis With Proximal Symphalangism | 4.9 | 7 | Citations (PDF) |
| 825 | Cardiac Autonomic Balance and QT Dispersion During Head‐Up Tilt Testing in Diabetics with and without Sensory Neuropathy | 3.1 | 5 | Citations (PDF) |
| 826 | Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes | 1.4 | 61 | Citations (PDF) |
| 827 | Macrophage Inflammatory Protein-1α Induces Hypercalcemia in Adult T-Cell Leukemia | 4.9 | 44 | Citations (PDF) |
| 828 | Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13–p12 in Japanese | 2.0 | 20 | Citations (PDF) |
| 829 | Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis | 1.9 | 17 | Citations (PDF) |
| 830 | Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts | 6.1 | 62 | Citations (PDF) |
| 831 | A Rare Case of Primary Hyperparathyroidism with Clear Cell Adenoma | 1.6 | 24 | Citations (PDF) |
| 832 | Active arthritis due to cryoglobulinemia based on HCV infection in a patient with RA Improvement of arthritis with IFN-.ALPHA. | 0.6 | 1 | Citations (PDF) |
| 833 | Inter- and intracellular signaling in secondary osteoporosis | 1.9 | 13 | Citations (PDF) |
| 834 | ?1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis | 6.1 | 32 | Citations (PDF) |
| 835 | High glucose levels inhibit focal adhesion kinase-mediated wound healing of rat peritoneal mesothelial cells | 5.3 | 45 | Citations (PDF) |
| 836 | Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1 | 2.7 | 37 | Citations (PDF) |
| 837 | Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells | 2.1 | 52 | Citations (PDF) |
| 838 | Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44 | 3.1 | 68 | Citations (PDF) |
| 839 | Efficacy of mizoribine treatment in patients with Sjögren’s syndrome: an open pilot trial | 1.9 | 12 | Citations (PDF) |
| 840 | Severe skin ulceration associated with Wegener’s granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E 1 | 1.9 | 0 | Citations (PDF) |
| 841 | β1 Integrin/Focal Adhesion Kinase-mediated Signaling Induces Intercellular Adhesion Molecule 1 and Receptor Activator of Nuclear Factor κB Ligand on Osteoblasts and Osteoclast Maturation | 2.2 | 72 | Citations (PDF) |
| 842 | Virilizing Adrenocortical Adenoma with Cushing's Syndrome, Thyroid Papillary Carcinoma and Hypergastrinemia in a Middle-Aged Woman | 1.6 | 9 | Citations (PDF) |
| 843 | Efficacy of mizoribine treatment in patients with Sj�gren?s syndrome: an open pilot trial | 1.9 | 2 | Citations (PDF) |
| 844 | Severe skin ulceration associated with Wegener?s granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E1 | 1.9 | 0 | Citations (PDF) |
| 845 | H-Ras/Mitogen-activated Protein Kinase Pathway Inhibits Integrin-mediated Adhesion and Induces Apoptosis in Osteoblasts | 2.2 | 43 | Citations (PDF) |
| 846 | A Case of von Hippel-Lindau Disease with Bilateral Pheochromocytoma, Renal Cell Carcinoma, Pelvic Tumor, Spinal Hemangioblastoma and Primary Hyperparathyroidism. | 1.6 | 13 | Citations (PDF) |
| 847 | Cell-to-Cell Adhesion via Intercellular Adhesion Molecule-1 and Leukocyte Function-Associated Antigen-1 Pathway Is Involved in 1.ALPHA.,25(OH)2D3, PTH and IL-1.ALPHA.-Induced Osteoclast Differentiation and Bone Resorption. | 1.6 | 52 | Citations (PDF) |
| 848 | Oxidized low density lipoprotein-induced LFA-1-dependent adhesion and transendothelial migration of monocytes via the protein kinase C pathway | 1.5 | 47 | Citations (PDF) |
| 849 | Role for adapter proteins in costimulatory signals of CD2 and IL-2 on NK cell activation | 2.2 | 13 | Citations (PDF) |
| 850 | Hypoxia-inducible factor-1α induces cell cycle arrest of endothelial cells | 1.4 | 71 | Citations (PDF) |
| 851 | Fractalkine, a CX
3
C‐chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP‐1 | 2.6 | 89 | Citations (PDF) |
| 852 | Down-regulation of α6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc | 1.4 | 12 | Citations (PDF) |
| 853 | CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells | 3.1 | 61 | Citations (PDF) |
| 854 | The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis | 2.2 | 22 | Citations (PDF) |
| 855 | Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: Involvement of cell cycle machinery | 6.1 | 10 | Citations (PDF) |
| 856 | Intercellular Adhesion Molecule 1 Discriminates Functionally Different Populations of Human Osteoblasts: Characteristic Involvement of Cell Cycle Regulators | 4.9 | 85 | Citations (PDF) |
| 857 | Ultrasonographic Evaluation of Lansoprazole-Induced Improvement of Submucosal Injury in Patients With Gastroesophageal Reflux | 0.7 | 11 | Citations (PDF) |
| 858 | An Elevation of Serum Immunoglobulin E Provides a New Aspect of Hyperthyroid Graves’ Disease | 4.0 | 38 | Citations (PDF) |
| 859 | Thyrocyte Proliferation by Cellular Adhesion to Infiltrating Lymphocytes through the Intercellular Adhesion Molecule-1/Lymphocyte Function-Associated Antigen-1 Pathway in Graves’ Disease1 | 4.0 | 19 | Citations (PDF) |
| 860 | Differential interaction of Cbl with Grb2 and CrkL in CD2-mediated NK cell activation | 2.2 | 11 | Citations (PDF) |
| 861 | Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis | 1.9 | 1 | Citations (PDF) |
| 862 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux | 0.7 | 0 | Citations (PDF) |
| 863 | Activation of Leukocyte Function-Associated Antigen-1 on Adult T-cell Leukemia Cells | 1.4 | 13 | Citations (PDF) |
| 864 | Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis | 6.1 | 52 | Citations (PDF) |
| 865 | Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53 1998, 75, 391-395 | | 15 | Citations (PDF) |
| 866 | A Critical Role for Cyclin C in Promotion of the Hematopoietic Cell Cycle by Cooperation with c-Myc | 2.5 | 46 | Citations (PDF) |
| 867 | Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia CellsBlood, 1998, 91, 3909-3919 | 5.0 | 76 | Citations (PDF) |
| 868 | Chondrocytes Are Regulated by Cellular Adhesion Through CD44 and Hyaluronic Acid Pathway | 4.9 | 153 | Citations (PDF) |
| 869 | Neurologic features of chronic minamata disease (organic mercury poisoning) and incidence of complications with aging | 1.8 | 31 | Citations (PDF) |
| 870 | Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1 | 4.9 | 105 | Citations (PDF) |
| 871 | CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function | 3.1 | 23 | Citations (PDF) |
| 872 | Differential Expression of Integrins α6 and α4 Determines Pathways in Human Peripheral CD4+ T Cell Differentiation | 1.6 | 9 | Citations (PDF) |
| 873 | Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes | 6.9 | 417 | Citations (PDF) |
| 874 | T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ | 37.9 | 883 | Citations (PDF) |
| 875 | Suppressive effect of interleukin-4 on the differentiation of M1 and HL60 myeloid leukemic cells | 2.9 | 5 | Citations (PDF) |
| 876 | Interleukin‐4 induces proliferation of adult T‐cell leukemia cells | 1.8 | 15 | Citations (PDF) |
| 877 | Lymphocyte interactions with endothelial cells | 6.9 | 679 | Citations (PDF) |
| 878 | Effect of hyperbaric oxygenation on macrophage function in mice | 2.1 | 52 | Citations (PDF) |
| 879 | B‐B Cell Interactions in the Spontaneous Activation of B Cells in Autoimmune NZB Mice | 2.2 | 4 | Citations (PDF) |
| 880 | Suppressive Activity of Interleukin 4 on the Induction of Antigen-specific Cytotoxic T Cells in Humans | 1.8 | 10 | Citations (PDF) |
| 881 | Effect of interleukin 1 (IL-1) on the levels of cytochrome P-450 involving IL-1 receptor on the isolated hepatocytes of rat | 2.1 | 46 | Citations (PDF) |
| 882 | Interleukin-4 as a potent inhibitor of bone resorption | 2.1 | 113 | Citations (PDF) |
| 883 | Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus | 3.1 | 31 | Citations (PDF) |
| 884 | Immunological functions and phenotypes of peripheral blood lymphocytes from human T-Cell leukemia virus-I carriers | 3.1 | 20 | Citations (PDF) |
| 885 | Inhibitory effect of anti-class II antibodies on human B-cell activation | 2.5 | 9 | Citations (PDF) |
| 886 | Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population | 0.2 | 70 | Citations (PDF) |
| 887 | Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab | 3.1 | 2 | Citations (PDF) |
| 888 | Title is missing! 0 | | 2 | Citations (PDF) |
| 889 | Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance | 0.2 | 37 | Citations (PDF) |
| 890 | Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance | 0.2 | 21 | Citations (PDF) |
| 891 | Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial | 6.1 | 49 | Citations (PDF) |
| 892 | Ageing Population and Landscape of Rheumatoid Arthritis Treatment in Japan | 0.0 | 1 | Citations (PDF) |
| 893 | Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus | 3.1 | 0 | Citations (PDF) |
| 894 | Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study | 1.9 | 4 | Citations (PDF) |
| 895 | Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry | 1.9 | 5 | Citations (PDF) |
| 896 | Serum cytokine levels towards precision medicine in Still’s disease: a subanalysis of a randomized controlled trial of tocilizumab | 1.9 | 6 | Citations (PDF) |
| 897 | Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active | 2.8 | 0 | Citations (PDF) |
| 898 | Novel therapies in treatments of SLE | 3.9 | 5 | Citations (PDF) |
| 899 | Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment | 6.9 | 9 | Citations (PDF) |
| 900 | Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still’s disease | 1.9 | 0 | Citations (PDF) |
| 901 | Predictors of damage accrual by organ domain in systemic lupus erythematosus | 1.9 | 2 | Citations (PDF) |
| 902 | Corrigendum to “Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease” [Respir. Investig. Volume 63, Issue 5, Pages 857–865] | 1.7 | 0 | Citations (PDF) |
| 903 | Addressing the disease burden of systemic lupus erythematosus | 1.9 | 1 | Citations (PDF) |
| 904 | Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study | 6.1 | 6 | Citations (PDF) |
| 905 | Long-term safety and efficacy of tocilizumab in adult-onset Still’s disease: open-label, long-term extension of the phase III trial | 1.9 | 1 | Citations (PDF) |
| 906 | Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials | 3.0 | 1 | Citations (PDF) |
| 907 | Impact of anti-drug antibodies and neutralising antibodies on safety and efficacy of ozoralizumab in rheumatoid arthritis | 1.9 | 0 | Citations (PDF) |
| 908 | Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE) | 1.9 | 1 | Citations (PDF) |
| 909 | Integrated safety analysis of filgotinib in Japanese patients with moderately to severely active rheumatoid arthritis over a treatment duration of up to 5 years | 1.9 | 0 | Citations (PDF) |
| 910 | Emerging treatments for systemic lupus erythematosus 0, 5, | | 0 | Citations (PDF) |
| 911 | Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence | 2.0 | 0 | Citations (PDF) |
| 912 | Emerging trends in the management of difficult-to-treat rheumatoid arthritis: targeted treatments and non-pharmacological interventions | 1.9 | 0 | Citations (PDF) |
| 913 | P179 Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study | 1.9 | 0 | Citations (PDF) |
| 914 | E102 Characterisation of patients with rheumatoid arthritis based on distinct patterns of pain improvement following treatment with filgotinib: a post hoc analysis of FINCH 1 | 1.9 | 0 | Citations (PDF) |
| 915 | Essential elements for guiding patient segmentation in precision pharmacotherapy for rheumatoid arthritis: lessons up to 2025 | 2.1 | 0 | Citations (PDF) |
| 916 | Immune regulation and cell metabolism in B cell subsets in patients with systemic lupus erythematosus | 4.9 | 1 | Citations (PDF) |
| 917 | Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting | 34.5 | 0 | Citations (PDF) |
| 918 | Long‐Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus | 2.2 | 0 | Citations (PDF) |
| 919 | Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study) | 2.0 | 0 | Citations (PDF) |
| 920 | Achievement of intermediate treatment targets for Still’s disease under tocilizumab treatment: a post-hoc analysis of the phase III trial | 2.5 | 0 | Citations (PDF) |
| 921 | Polyarteritis nodosa and sarcoidosis presenting with myalgia and myositis-mimicking magnetic resonance imaging findings: A report of two cases | 0.9 | 0 | Citations (PDF) |
| 922 | Zero Time‐to‐Echo Imaging of the Hand and Wrist in Rheumatoid Arthritis Patients | 3.4 | 1 | Citations (PDF) |
| 923 | A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis | 2.2 | 0 | Citations (PDF) |
